Back to Resource Library
01:30:42
Webinar Description:
This webinar will discuss the specific characteristics and biologic activity of a specialized population of cells derived from the vascular endothelium. These cells produce signaling molecules that stimulate the intrinsic progenitor cells that are resident is many tissues.Key Learning Objectives:
The Role of Vascular Niche Endothelial Cells in Tissue Healing and Regeneration
Part 3 of 5 of the ISCT Orthopedic & Musculoskeletal Therapies Committee Webinar Series
Sponsored By:
Chair:
Scott Rodeo, MDAttending Orthopedic SurgeonThe Hospital for Special SurgeryUnited States
Dr. Scott Rodeo is Professor of Orthopaedic Surgery at Weill Medical College of Cornell University and is an Attending Surgeon at the New York-Presbyterian Hospital and the Hospital for Special Surgery, where he is Co-Chief Emeritus of the Sports Medicine and Shoulder Service, Vice Chair of Orthopaedic Research, and Co-Director of the Orthopaedic Soft Tissue Research Program. He also serves as Director of the Center for Regenerative Medicine at Hospital for Special Surgery. Rodeo is Head Team Physician for the New York Giants Football Team, and he served as a Team Physician for the United States Olympic Team in 2004, 2008, 2012, and 2016. His clinical practice involves orthopaedic sports medicine, with specialty interest in complex knee reconstruction (ligament, meniscus, and cartilage surgery), tendon repair in the shoulder and other joints, and shoulder instability. He runs a translational research laboratory program investigating the cellular and molecular mechanisms of soft tissue repair. Rodeo graduated cum laude from Stanford University, where he completed his undergraduate work while competing on the Stanford Swimming Team. He completed medical school graduating with honors from Cornell University Medical College.
Speakers:
Shahin Rafii, MDWeill Cornell Medical CollegeUnited States
Shahin Rafii's laboratory focuses on stem cell biology and angiogenesis uses in vivo mouse model and mouse and human genetics, tissue culture approaches and molecular biology to model angiognesis, cancer and stem cell metabolic regulation. Genetic, genomic, molecular and cell biological techniques are combined to achieve a systems level understanding of these complex processes.
Currently, Rafii's work is focused on identifying the molecular and cellular pathways involved in organ regeneration and tumor growth. He has established the concept that vascular endothelial cells are not just inert plumbing to deliver oxygen and nutrients, but also by production of tissue-specific growth factors, defined as angiocrine factors, support organ regeneration and tumor proliferation. He has shown that bone marrow endothelial cells by elaboration of angiocrine factors, such as Notch ligands, support stem cell self-renewal and differentiation into lymphoid and myeloid progenitors. He has recently demonstrated that liver and lung endothelial cells are endowed with unique phenotypic and functional attributes and by production of unique instructive growth factors contribute to the hepatic and alveolar regeneration.
He employed this knowledge to induce differentiation of the murine and human pluripotent embryonic stem cells into functional and engraftable vascular and hematopoietic derivatives. He developed screening approaches to exploit endothelial cells as a vascular niche platform to identify as yet unrecognized novel angiocrine factors that instruct tumor proliferation as well as orchestrating stem cell self-renewal and differentiation. As such, studies of c-ets-1, Fos, Foxo and Nrf2 dependent signaling and gene regulation in oxidative stress response and stem cell regulation on signaling pathways that control differentiation and de-differentiation of stem cells in vitro and in vivo models, and the role of matrix metallo proteases in developmentally controlled lung generation as well as pathological cell movements and tissue invasiveness. He is developing pre-clinical and clinical models to interrogate the potential of organ-specific endothelial cells in repairing injured organs or to target tumor vasculature.
Daniel Nolan, PhDDirector of External ResearchAngiocrine BioscienceUnited States
Daniel J. Nolan, Ph.D. is Director of External Research at Angiocrine Bioscience, contributing to the development of the E-CEL endothelial cell platform for research and clinical applications. An alumnus of Stony Brook University, Daniel remained there for his graduate studies ultimately performing his research in the laboratory of Dr. Vivek Mittal. Dr. Mittal fostered Daniel’s interest in vascular biology with work centered on the temporal contribution of endothelial progenitor cells to tumor vasculature. His exposure to and responsibility for a wide range of advanced technology led to his recruitment by Dr. Shahin Rafii at Weill Cornell Medical College. This became fertile grounds for advances as Dr. Rafii’s team was rapidly accelerating their understanding of the capacities of the E-CEL platform (then known as E4ORF1+ endothelial cells) and Daniel was transforming the technological landscape of protocols within the laboratory to achieve these advances. His own work focused on the distinctions between the endothelial cells of the various tissues. The protocols he developed were the foundations to establish the murine E-CEL UVEC prototype series of tissue specific microvascular endothelial cells and transitioning from research grade materials to the industrial and clinical levels. As Angiocrine Bioscience has grown, Daniel’s role has transitioned to various responsibilities. His current roles include overseeing domestic and international patent portfolios and being the scientific and technical liaison between Angiocrine Bioscience and the numerous hospitals performing clinical trials with the E-CEL technology.
Diego Correa, MD, PhDSenior Director, Medical Strategy Lead at the Cell and Gene Therapy Center of ExcellenceIQVIAUnited States
Dr. Correa is an expert in Cell Biology, with special emphasis on adult Mesenchymal Stem Cells (MSC) and their clinical applications in Regenerative Medicine.
He holds various patent submissions; is author and co-author of more than 60 scientific publications in renowned journals; serves as member of steering committees on international scientific organizations such as ISCT. He has also participated in diverse entrepreneurial activities in the areas of Regenerative Medicine and in various Scientific Advisory Boards in companies within the Regenerative Medicine field.